Clinical Trials Logo

Clinical Trial Summary

This study is to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419 in Patients with Peripheral Neuropathic Pain


Clinical Trial Description

This is a single center, three-period, complete crossover, double-blind, randomised, placebo- and active-controlled study to compare the preliminary efficacy of a single dose of SR419 to placebo and active control in patients with peripheral neuropathic pain. The study also aims to evaluate the safety, tolerability, and PK of single doses of SR419 in patients with peripheral neuropathic pain. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04494815
Study type Interventional
Source Shanghai SIMR Biotechnology Co., Ltd.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 18, 2020
Completion date July 31, 2022

See also
  Status Clinical Trial Phase
Completed NCT03733886 - Burst Spinal Cord Stimulation for Neuropathic Pain. N/A
Recruiting NCT04431778 - Evaluation of the Efficacy and Tolerance of Low Doses of Ethosuximide in the Treatment of Peripheral Neuropathic Pain Phase 2
Completed NCT03191136 - Clinical Trial to Assess the Effect of Food on the Pharmacokinetics of YHD1119 in Healthy Volunteers Phase 1
Completed NCT02100046 - Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain. Phase 2
Completed NCT05416931 - ACD440 Gel in Peripheral Neuropathic Pain Phase 2
Completed NCT06234917 - Increasing Sensori-Motor Rhythm Activity by EEG-Neurofeedback to Reduce the Impact of Pain on Daily Functioning N/A
Completed NCT03009500 - Randomized Controlled Trial of Efficacy and Safety of Local Anesthetics and Steroids for Chronic Peripheral Post-traumatic Neuropathic Pain Phase 3
Completed NCT01524796 - NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions in Denmark
Completed NCT02985216 - Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain Phase 3
Recruiting NCT04171453 - Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablets
Completed NCT01737294 - Observation of the Use of QUTENZAâ„¢ in Standard Clinical Practice N/A
Active, not recruiting NCT05890053 - To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia Phase 3
Completed NCT05219812 - A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain Phase 2
Terminated NCT01293851 - Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Nerve Damage
Completed NCT02209896 - BlueWind Reprieve System for the Treatment of PNP N/A
Completed NCT01240148 - Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers Phase 1
Recruiting NCT05817591 - Response Profiles to High-concentration Capsaicin Desensitization in Patients With Peripheral Neuropathic Pain With or Without Allodynia: a Regional Multicenter Prospective Cohort